Forecast

There is no analyst data available for this company.

News Go to news feed

Orexo widens quarterly loss, revenue falls short of expectations

Orexo reports a larger net loss for Q2 with revenue of SEK 3.50 million, well below the consensus estimate of SEK 5 million; earnings per share -2.92 SEK, EBIT -103.3 million SEK and EBITDA -95.1 million SEK. Revenue declined year‑on‑year, and higher operating expenses reflect ongoing R&D spending and organizational adjustments following the sale of Zubsolv in the US. The company is advancing its emergency‑medication pipeline, notes external interest in the AmorphOX technology and is holding partnership talks. Orexo plans a regulatory‑relevant study for OX640 from Q4 2026 with results in Q1 2027, intends to refile the NDA for Izipry in Q3 2026 and targets a possible FDA approval in Q1 2027. To support growth and clarify DOJ matters, Orexo is exploring additional financing options. » More on de.investing.com
Orexo misses Q3 revenue expectations, stock plunges after results

Orexo reported third-quarter net sales of SEK 119 million versus expected SEK 128.1 million and recorded a negative EBITDA of SEK 9.8 million. The share fell 14.8% to SEK 31.9 after the figures; the company cites currency effects and seasonally reduced wholesale inventories as reasons. Despite the short-term weakness, Orexo highlights progress on its AmorphOX platform, including promising preclinical data for the intranasal semaglutide program OX472 and a USD 50.9 million BARDA funding award for the emergency program OX390. Liquidity fell to SEK 105.6 million, but management reconfirms the annual outlook and still aims for positive EBITDA in 2025. » More on de.investing.com
Orexo AB exceeds revenue expectations, shares fall despite strong gross margin

Orexo AB reported revenue of SEK 180 million in the second quarter of 2025, significantly surpassing forecasts, but the stock still declined by 6.17%. Despite an improved gross margin and strong performance in the US market, EBITDA remains negative, indicating ongoing financial challenges and cautious investor sentiment. CEO Nikolay Sorensen emphasized the company's focus on cost discipline and patient access, while maintaining a positive EBITDA outlook for the full year. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Orexo has already paid €4.99 in dividends. The last payout was in September 2022.

Financials

In the last quarter, Orexo had revenue of €315.83K and net profit of -€9.06M

(EUR)	Jun 2026	YoY
Revenue	315.83K	97.02%
Gross profit	306.81K	96.89%
Net profit	-9.06M	153.64%
EBITDA	-8.57M	845.74%

Fundamentals

Metric	Value
Market capitalization	€43.43M
Number of shares	35.13M
52-week high/low	€2.77 - €1.24
Dividends	No
Beta	0.89
P/E ratio	-1.49
PEG ratio	0.02
P/B ratio	1.70
P/S ratio	3.53

Company profile

Orexo AB (publ), ein Spezialpharmaunternehmen, entwickelt und vermarktet Arzneimittel und digitale Therapien in den Vereinigten Staaten, Europa und dem Vereinigten Königreich. Zu den Produkten des Unternehmens gehören Zubsolv-Tabletten zur Behandlung von Opioidabhängigkeit, Abstral zur Behandlung von Durchbruchschmerzen bei Krebspatienten und Edluar zur Behandlung von kurzzeitiger Schlaflosigkeit. Die Entwicklungsprodukte des Unternehmens umfassen OX124, ein Medikament zur Naloxon-Rettung, OX125, ein Medikament zur Nalmefen-Rettung, OX640, ein Medikament zur Behandlung von allergischen Reaktionen, und OX338, eine sublinguale Tablettenformulierung von Ketorolac zur Behandlung von mäßigen bis starken Schmerzen. Außerdem entwickelt das Unternehmen das Programm OX-MPI zur Behandlung von mikrovaskulären Erkrankungen bei chronischen Entzündungen. Die digitalen Therapien des Unternehmens umfassen die Deprexis-Therapie zur Behandlung von leichten bis schweren Depressionen, Vorvida zur Behandlung von Alkoholproblemen und Modia zur Behandlung von Opioidkonsumstörungen. Orexo AB (publ) wurde 1994 gegründet und hat seinen Hauptsitz in Uppsala, Schweden.